{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:37:18Z","timestamp":1794328638925,"version":"4.9.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.esmoop.2025.105914","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T22:45:52Z","timestamp":1764888352000},"page":"105914","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-world evaluation of interstitial lung disease\/pneumonitis in patients treated with trastuzumab deruxtecan for HER2-positive advanced or recurrent gastric cancer: a postmarketing surveillance study in Japan"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-4850","authenticated-orcid":false,"given":"H.","family":"Kawakami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4339-9543","authenticated-orcid":false,"given":"K.","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3682-502X","authenticated-orcid":false,"given":"W.","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5572-743X","authenticated-orcid":false,"given":"K.","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2025.105914_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105914_bib2","article-title":"The global, regional and national burden of stomach cancer and its attributable risk factors from 1990 to 2019","volume":"12","author":"Song","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105914_bib5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","article-title":"HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer","volume":"18","author":"Van Cutsem","year":"2015","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105914_bib6","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10120-014-0430-7","article-title":"Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer","volume":"18","author":"Kurokawa","year":"2015","journal-title":"Gastric Cancer"},{"issue":"20","key":"10.1016\/j.esmoop.2025.105914_bib7","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105914_bib8","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","article-title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study","volume":"18","author":"Doi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105914_bib9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1470-2045(19)30088-9","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study","volume":"20","author":"Shitara","year":"2019","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2025.105914_bib10","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105914_bib11","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1200\/JCO.22.00575","article-title":"Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial","volume":"41","author":"Yamaguchi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105914_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920986518","article-title":"Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer","volume":"13","author":"Kotani","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105914_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","article-title":"Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)","volume":"26","year":"2023","journal-title":"Gastric Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105914_bib15","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105914_bib16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1200\/OP.22.00480","article-title":"Real-world perspectives and practices for pneumonitis\/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2\u2013expressing metastatic breast cancer","volume":"19","author":"Rugo","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2025.105914_bib17","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.bjc.6602063","article-title":"Interstitial lung disease associated with drug therapy","volume":"91","author":"Camus","year":"2004","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105914_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105914_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer","volume":"12","author":"J\u00e4nne","year":"2022","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105914_bib20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"},{"key":"10.1016\/j.esmoop.2025.105914_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)\u2013related interstitial lung disease\/pneumonitis\u2014focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105914_bib22","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s10147-023-02414-x","article-title":"Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan","volume":"28","author":"Baba","year":"2023","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105914_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105914_bib27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105914_bib28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10120-024-01560-z","article-title":"Prognostic and predictive factors for the efficacy and safety of trastuzumab deruxtecan in HER2-positive gastric or gastroesophageal junction cancer","volume":"28","author":"Jubashi","year":"2025","journal-title":"Gastric Cancer"},{"issue":"16","key":"10.1016\/j.esmoop.2025.105914_bib29","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2217\/fon-2019-0102","article-title":"Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma","volume":"15","author":"Baba","year":"2019","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105914_bib30","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/cas.14710","article-title":"Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer","volume":"112","author":"Saito","year":"2021","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105914_bib31","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jtho.2018.11.022","article-title":"Interstitial lung disease onset and its risk factors in Japanese patients with ALK-positive NSCLC after treatment with crizotinib","volume":"14","author":"Gemma","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105914_bib32","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.jtho.2020.08.025","article-title":"Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M-positive NSCLC treated with osimertinib in Japan","volume":"15","author":"Gemma","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105914_bib33","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/OP.23.00097","article-title":"Detecting and managing T-DXd-related interstitial lung disease: the five \u201cS\u201d rules","volume":"19","author":"Tarantino","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105914_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198886","article-title":"Pre-existing interstitial lung disease as a risk factor for pneumonitis associated with ramucirumab and paclitaxel in patients with gastric cancer: the impact of usual interstitial pneumonia","volume":"13","author":"Koyama","year":"2018","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105914_bib35","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/cas.12550","article-title":"Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer","volume":"105","author":"Gemma","year":"2014","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105914_bib36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jgo.2019.09.009","article-title":"Advancing age and the risk of bleomycin pulmonary toxicity in a largely older cohort of patients with newly diagnosed Hodgkin Lymphoma","volume":"11","author":"Thomas","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105914_bib37","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/0003-4819-127-5-199709010-00003","article-title":"Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group","volume":"127","author":"Alarc\u00f3n","year":"1997","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105914_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.130466","article-title":"Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan","volume":"41","author":"Koike","year":"2014","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105914_bib39","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","article-title":"Consensus statement for the diagnosis and treatment of drug-induced lung injuries","volume":"51","author":"Kubo","year":"2013","journal-title":"Respir Investig"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925017843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:09:27Z","timestamp":1773868167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925017843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2059702925017843"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105914","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evaluation of interstitial lung disease\/pneumonitis in patients treated with trastuzumab deruxtecan for HER2-positive advanced or recurrent gastric cancer: a postmarketing surveillance study in Japan","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105914","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105914"}}